MicroRNA‑590‑3p enhances the radioresistance in glioblastoma cells by targeting LRIG1

Chen,Long; Wang,Wenhua; Zhu,Shengqiang; Jin,Xuegang; Wang,Jian; Zhu,Jianfang; Zhou,Youxin

doi:10.3892/etm.2017.4697

MicroRNA‑590‑3p enhances the radioresistance in glioblastoma cells by targeting LRIG1

Authors:
- Long Chen
- Wenhua Wang
- Shengqiang Zhu
- Xuegang Jin
- Jian Wang
- Jianfang Zhu
- Youxin Zhou
View Affiliations

Affiliations: Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Neurosurgery, The Affiliated Hospital of Nanjing University of Chinese Medicine, Kunshan, Jiangsu 215300, P.R. China
Published online on: June 28, 2017 https://doi.org/10.3892/etm.2017.4697
Pages: 1818-1824

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNA (miR)‑590 has been found to serve potential roles in cancer development; however, the expression and function of miR‑590 in human gliomas remains to be elucidated. The present study aimed to investigate the expression of miR‑590 in human glioma tissues and radioresistant human glioblastoma cells (U251R), and to determine the effect and related molecular mechanism of miR‑590‑3p on the radiosensitivity of U251R cells in vitro. The results from reverse transcription‑quantitative polymerase chain reaction indicated that miR‑590‑3p was upregulated in human glioma tissues and radioresistant human glioblastoma cells, and that miR‑590‑3p expression was higher in high grade than in low grade gliomas. In vitro experiments revealed that the miR‑590‑3p inhibitor enhanced the radiosensitivity of U251R cells by suppressing cell viability, decreasing colony formation capacity and increasing cell apoptosis rate, as demonstrated by MTT, colony formation and flow cytometry analyses. A luciferase reporter assay demonstrated that leucine‑rich repeats and immunoglobulin‑like domains protein 1 (LRIG1) was a direct target of miR‑590‑3p. Furthermore, it was demonstrated that the effect of miR‑590‑3p suppression on cell viability, colony formation capacity and cell apoptosis rate was attenuated by the knockdown of LRIG1 in the U251R cells. In conclusion, the present study revealed that miR‑590‑3p was upregulated in human glioma tissues and radioresistant human glioblastoma cells, and miR‑590‑3p contributes to the radioresistance of human glioblastoma cells by directly targeting LRIG1. These findings may provide potential therapeutic strategies to prevent radioresistance in human gliomas.

View Figures

View References

1	Dolecek TA, Propp JM, Stroup NE and Kruchko C: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14 Suppl 5:v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
2	Mihailović G, Marković M, Zivković N, Mihailović G, Marković M, Berisavac I and Spaić M: Epidemiological features of brain tumors. Srp Arh Celok Lek. 141:823–829. 2013.(In Serbian). View Article : Google Scholar : PubMed/NCBI
3	Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
4	Wang Y and Jiang T: Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. Cancer Lett. 331:139–146. 2013. View Article : Google Scholar : PubMed/NCBI
5	Carlsson SK, Brothers SP and Wahlestedt C: Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med. 6:1359–1370. 2014. View Article : Google Scholar : PubMed/NCBI
6	Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomasa: Clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
7	Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, et al: Genetic pathways to glioblastoma: A population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
9	Atkins RJ, Ng W, Stylli SS, Hovens CM and Kaye AH: Repair mechanisms help glioblastoma resist treatment. J Clin Neurosci. 22:14–20. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
11	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
12	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:pp. 2999–3004. 2004; View Article : Google Scholar : PubMed/NCBI
13	Sevignani C, Calin GA, Nnadi SC, Shimizu M, Davuluri RV, Hyslop T, Demant P, Croce CM and Siracusa LD: MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci USA. 104:pp. 8017–8022. 2007; View Article : Google Scholar : PubMed/NCBI
14	Miranda PJ, Vimalraj S and Selvamurugan N: A feedback expression of microRNA-590 and activating transcription factor-3 in human breastcancer cells. Int J Biol Macromol. 72:145–150. 2015. View Article : Google Scholar : PubMed/NCBI
15	Chu Y, Ouyang Y, Wang F, Zheng A, Bai L, Han L, Chen Y and Wang H: MicroRNA-590 promotes cervical cancer cell growth and invasion by targeting CHL1. J Cell Biochem. 115:847–853. 2014. View Article : Google Scholar : PubMed/NCBI
16	Xiao X, Tang C, Xiao S, Fu C and Yu P: Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res. 20:537–544. 2013. View Article : Google Scholar : PubMed/NCBI
17	Yang H, Zheng W, Zhao W, Guan C and An J: Roles of miR-590-5p and miR-590-3p in the development of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 33:804–811. 2013.(In Chinese). PubMed/NCBI
18	Yokdang N, Hatakeyama J, Wald JH, Simion C, Tellez JD, Chang DZ, Swamynathan MM, Chen M, Murphy WJ, Iii KL Carraway and Sweeney C: LRIG1 opposes epithelial-to- mesenchymal transition and inhibits invasion of basal-like breast cancer cells. Oncogene. 35:2932–2947. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kou C, Zhou T, Han X, Zhuang H and Qian H: LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer. Biochem Biophys Res Commun. 464:519–525. 2015. View Article : Google Scholar : PubMed/NCBI
20	Sheu JJ, Lee CC, Hua CH, Li CI, Lai MT, Lee SC, Cheng J, Chen CM, Chan C, Chao SC, et al: LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling. Oncogene. 33:1375–1384. 2014. View Article : Google Scholar : PubMed/NCBI
21	Ye F, Gao Q, Xu T, Zeng L, Ou Y, Mao F, Wang H, He Y, Wang B, Yang Z, et al: Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J Neurooncol. 94:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yang JA, Liu BH, Shao LM, Guo ZT, Yang Q, Wu LQ, Ji BW, Zhu XN, Zhang SQ, Li CJ and Chen QX: LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway. Int J Clin Exp Pathol. 8:3580–3590. 2015.PubMed/NCBI
23	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-tie quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	One in three newly diagnosed cancer patients now receives radiation therapy. Oncology (Williston Park). 10:17761996.PubMed/NCBI
26	Chen G, Zhu W, Shi D, Lv L, Zhang C, Liu P and Hu W: MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep. 23:997–1003. 2010.PubMed/NCBI
27	Deng X, Ma L, Wu M, Zhang G, Jin C, Guo Y and Liu R: miR-124 radiosensitizes human glioma cells by targeting CDK4. J Neurooncol. 114:263–274. 2013. View Article : Google Scholar : PubMed/NCBI
28	Guo P, Lan J, Ge J, Nie Q, Guo L, Qiu Y and Mao Q: MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Exp Cell Res. 320:200–208. 2014. View Article : Google Scholar : PubMed/NCBI
29	Li W, Guo F, Wang P, Hong S and Zhang C: miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Curr Mol Med. 14:185–195. 2014. View Article : Google Scholar : PubMed/NCBI
30	Upraity S, Kazi S, Padul V and Shirsat NV: MiR-224 expression increases radiation sensitivity of glioblastoma cells. Biochem Biophys Res Commun. 448:225–230. 2014. View Article : Google Scholar : PubMed/NCBI
31	Thomasson M, Hedman H, Guo D, Ljungberg B and Henriksson R: LRIG1 and epidermal growth factor receptor in renal cell carcinoma: A quantitative RT-PCR and immunohistochemical analysis. Brit J Cancer. 89:1285–1289. 2003. View Article : Google Scholar : PubMed/NCBI
32	Nagata M, Nakamura T, Sotozono C, Inatomi T, Yokoi N and Kinoshita S: LRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasia. PLoS One. 9:e931642014. View Article : Google Scholar : PubMed/NCBI
33	Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H and Henriksson R: Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol. 111:238–246. 2006. View Article : Google Scholar : PubMed/NCBI
34	Johansson M, Oudin A, Tiemann K, Bernard A, Golebiewska A, Keunen O, Fack F, Stieber D, Wang B, Hedman H and Niclou SP: The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro Oncol. 15:1200–1211. 2013. View Article : Google Scholar : PubMed/NCBI
35	Mao F, Wang B, Xiao Q, Xi G, Sun W, Zhang H, Ye F, Wan F, Guo D, Lei T and Chen X: A role for LRIG1 in the regulation of malignant glioma aggressiveness. Int J Oncol. 42:1081–1087. 2013.PubMed/NCBI
36	Ye F, Guo DS, Niu HQ, Tao SZ, Ou YB, Lu YP and Lei T: Molecular mechanism of LRIG1 cDNA-induced apoptosis in human glioma cell line H4. Ai Zheng. 23:1149–1154. 2004.(In Chinese). PubMed/NCBI
37	Xie R, Yang H, Xiao Q, Mao F, Zhang S, Ye F, Wan F, Wang B, Lei T and Guo D: Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties ofglioma cells via EGFR/Akt/c-Myc activation. Oncol Rep. 29:177–184. 2013.PubMed/NCBI
38	Mao F, Wang B, Xi G, Sun W, Zhang H, Ye F, Guo D and Lei T: Effects of RNAi-mediated gene silencing of LRIG1 on proliferation and invasion of glioma cells. J Huazhong Univ Sci Technolog Med Sci. 32:227–232. 2012. View Article : Google Scholar : PubMed/NCBI
39	Wu X, Hedman H, Bergqvist M, Bergström S, Henriksson R, Gullbo J, Lennartsson J, Hesselius P and Ekman S: Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity. Acta Oncol. 51:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
40	Sheu JJ, Lee CC, Hua CH, Li CI, Lai MT, Lee SC, Cheng J, Chen CM, Chan C, Chao SC, et al: LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling. Oncogene. 33:1375–1384. 2013. View Article : Google Scholar : PubMed/NCBI
41	Guo Z, Chen Q, Liu B, Tian D, Zhang S and Li M: LRIG1 enhances chemosensitivity by modulating BCL-2 expression and receptor tyrosine kinase signaling in glioma cells. Yonsei Med J. 55:1196–1205. 2014. View Article : Google Scholar : PubMed/NCBI
42	Qi XC, Xie DJ, Yan QF, Wang YR, Zhu YX, Qian C and Yang SX: LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2. Biochem Biophys Res Commun. 437:565–572. 2013. View Article : Google Scholar : PubMed/NCBI
43	Wang X, Xiao Q, Xing X, Tian C, Zhang H, Ye F, Wan F, Wang B, Guo D and Lei T: LRIG1 enhances cisplatin sensitivity of glioma cell lines. Oncol Res. 20:205–211. 2012. View Article : Google Scholar : PubMed/NCBI